Raludotatug deruxtecan — Investigational Agent
Antibody-Drug Conjugate · Phase 1/2 · Daiichi Sankyo / Merck
Mechanism of Action
Raludotatug deruxtecan is an ADC targeting CDH6 (Cadherin-6). It consists of a humanized anti-CDH6 monoclonal antibody linked to a topoisomerase I inhibitor payload (deruxtecan, a derivative of exatecan) via a tetrapeptide-based cleavable linker. Upon binding to CDH6 on tumor cells, the ADC is internalized, and the linker is cleaved by lysosomal proteases. The released deruxtecan induces DNA damage and cell death, while also exerting a bystander effect on nearby CDH6-negative cells.
Investigational Indications
- Ovarian cancer
- Renal cell carcinoma